Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Omobolanle Ibitayo Olagunju"'
Autor:
Adeniyi Olagunju, Adeola Fowotade, Ajibola Olagunoye, Temitope Olumuyiwa Ojo, Bolanle Olufunlola Adefuye, Adeniyi Francis Fagbamigbe, Akindele Olupelumi Adebiyi, Omobolanle Ibitayo Olagunju, Olabode Taiwo Ladipo, Abdulafeez Akinloye, Babatunde Ayodeji Adeagbo, Adedeji Onayade, Oluseye Oladotun Bolaji, Christian Happi, Steve Rannard, Andrew Owen
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Abstract Objectives To investigate the efficacy and safety of repurposed antiprotozoal and antiretroviral drugs, nitazoxanide and atazanavir/ritonavir, in shortening the time to clinical improvement and achievement of SARS-CoV-2 polymerase chain reac
Externí odkaz:
https://doaj.org/article/6708633f3a154f358761faaee9a0c1ce
Autor:
Adeola Fowotade, Folasade Bamidele, Boluwatife Egbetola, Adeniyi Francis Fagbamigbe, Babatunde Ayodeji Adeagbo, Bolanle Olufunlola Adefuye, Ajibola Olagunoye, Temitope Olumuyiwa Ojo, Akindele Olupelumi Adebiyi, Omobolanle Ibitayo Olagunju, Olabode Taiwo Ladipo, Abdulafeez Akinloye, Adedeji Onayade, Oluseye Oladotun Bolaji, Steve Rannard, Christian Happi, Andrew Owen, Adeniyi Olagunju
SummaryBackgroundFinding effective therapeutics for COVID-19 continues to be an urgent need, especially considering use context limitations and high cost of currently approved agents. The NACOVID trial investigated the efficacy and safety of repurpos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49ccda5d21f1061a5577c2004ebaca1c
https://doi.org/10.1101/2022.02.03.22270152
https://doi.org/10.1101/2022.02.03.22270152
Autor:
Olabode Taiwo Ladipo, Adeniyi Francis Fagbamigbe, Abdulafeez Akinloye, A.A. Onayade, Steve P. Rannard, Akindele Olupelumi Adebiyi, Christian T. Happi, Ajibola Olagunoye, Andrew Owen, Temitope Olumuyiwa Ojo, Omobolanle Ibitayo Olagunju, Babatunde Ayodeji Adeagbo, Adeniyi Olagunju, Adeola Fowotade, Bolanle O. Adefuye, Oluseye O. Bolaji
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Trials
Trials
Objectives To investigate the efficacy and safety of repurposed antiprotozoal and antiretroviral drugs, nitazoxanide and atazanavir/ritonavir, in shortening the time to clinical improvement and achievement of SARS-CoV-2 polymerase chain reaction (PCR